Activist Investor With 5.5% Stake Demands Immediate Sale of CVRx
CVRX sits 29% above its 52-week low of $2.2.
Summary
Jorey Chernett, a 5.5% beneficial owner, has publicly urged the CVRx board to launch an immediate sale process to a strategic acquirer, arguing Barostim's value is best realized under a larger medical device company. The letter demands retention of an independent advisor, aggressive cost cuts, and suspension of standalone spending during the review. This follows a turbulent period: CFO resignation in June, CRO termination in August, a guidance cut on August 6, and a securities fraud investigation announced August 14. The activist pressure adds a new strategic dimension and could force board action, making the stock a potential takeover play. Watch for any board response or formal strategic review announcement.
At the time of this announcement, CVRX was trading at $2.84 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $75.7M. The 52-week trading range was $2.20 to $11.30. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: PR Newswire.